Background: N6-methyladenine (m6A) methylation, known as a kind of RNA methylation regulator, has become a hotspot for research in the life sciences in recent years. The existing studies revealed that m6A regulators helped to regulate the progression of several malignant tumors. However, the expression mode and prognostic value of m6A regulators in ovarian cancer have not been fully elucidated.
Methods: ONCOMINE, GEPIA, Human protein atlas, Kaplan-meier, UALCAN, cBioPortal, GeneMANIA, DAVID, Sring, and Metascape were utilized in this study.
Results: In this study, through a comprehensive use of multiple database systems, m6A regulators-induced mRNA and protein expression levels and their prognostic value in the epithelial ovarian cancer of various histological types were analyzed. Moreover, the interaction, epigenetic changes and functional enrichment of m6A regulators in ovarian cancer were also discussed. By analyzing the transcription levels and survival curves of m6A regulators in serous and endometrioid ovarian cancer s, it was found that FTO, YTHDF1, YTHDF2 and IGF2BP1 could be used as the therapeutic target for serous ovarian cancer. YTHDC2 and IGF2BP2 could serve as endometrioid ovarian cancer’s therapeutic target and potential prognostic biomarker, respectively.
Conclusions: Our results may provide novel insights for the selection of therapeutic targets and prognostic biomarkers for serous and endometrioid ovarian cancers.